Molecular Partners Ag (MOLN) Current Assets (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Current Assets of $105899.4 for Q1 2026, down 30.48% year-over-year from $152326.0 in Q1 2025, and down 12.63% quarter-over-quarter from $121208.3 in Q4 2025.
Molecular Partners Ag (MOLN) Current Assets (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Current Assets for 7 consecutive years, with $105899.4 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 30.48% year-over-year to $105899.4; the TTM figure through Mar 2026 stood at $105899.4 (down 30.48% YoY), while the FY2025 annual figure was $121208.3, down 99.93% from the prior year.
- Current Assets declined to $105899.4 in Q1 2026 per MOLN's latest filing, from $121208.3 in the prior quarter.
- Across five years, Current Assets topped out at $302.6 million in Q2 2022 and bottomed at $105899.4 in Q1 2026.
- Historically, Current Assets has averaged $82.0 million across 5 years, with a median of $256753.4 in 2023.
- Annual changes were most pronounced in 2022 — Current Assets soared 55.2% — and 2025, when it sank 99.93%.
- Molecular Partners Ag's Current Assets stood at $264.4 million in 2022, then dropped by 17.95% to $217.0 million in 2023, then decreased by 18.83% to $176.1 million in 2024, then tumbled by 99.93% to $121208.3 in 2025, then retreated by 12.63% to $105899.4 in 2026.
- Business Quant data shows MOLN's Current Assets at $105899.4 in Q1 2026, $121208.3 in Q4 2025, and $136211.9 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 1.76 Bn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | 105,899.44 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 105,899.44 |
| Dec 31, 2025 | 121,208.32 |
| Sep 30, 2025 | 136,211.93 |
| Jun 30, 2025 | 145,631.70 |
| Mar 31, 2025 | 152,326.05 |
| Dec 31, 2024 | 176.12 Mn |
| Sep 30, 2024 | 172,589.76 |
| Jun 30, 2024 | 183.12 Mn |
| Mar 31, 2024 | 206,435.91 |
| Dec 31, 2023 | 216.97 Mn |
| Sep 30, 2023 | 239,940.49 |
| Jun 30, 2023 | 248.97 Mn |
| Mar 31, 2023 | 256,753.41 |
| Dec 31, 2022 | 264.44 Mn |
| Sep 30, 2022 | 283,392.06 |
| Jun 30, 2022 | 302.65 Mn |
| Mar 31, 2022 | 328,749.29 |
| Dec 31, 2021 | 178.07 Mn |
| Sep 30, 2021 | 182,593.58 |
| Dec 31, 2020 | 196.69 Mn |